… pylori, and Chlamydia pneumoniae. Infectious agents … restenosis,[111] [134] and, because
rapamycin can inhibit its … in preventing infection-induced in-stent restenosis might be the use …

… Indeed, the presence of Chlamydia pneumoniae in blood and … introduce new therapeutic
solutions against the in-stent restenosis… , “Rapamycin can inhibit the development of Chlamydia …

… rapamycin that are clinically utilized in DES to counteract … Smith, showed inhibitory effect
on Chlamydia pneumonia-… Unfortunately, although the risks of in-stent thrombosis and other …

… growth inhibition of two chlamydial species, C. pneumoniae and Chlamydia trachomatis …
use, for example in mouthwashes for preventing pneumonia. Other non-antibiotic compounds …

… In-stent restenosis and neoatherosclerosis after … BBR (50 µmol/L) inhibited chlamydia
pneumoniae infection … that by inhibiting the activity of the mammalian target of rapamycin (mTOR) …

… Chlamydia was developed. Later, when cell culture methods for … In this work, only the name
Chlamydia pneumoniae is used. … An inclusion can also be released from the cell only partly …

… Similarly, BBR attenuated Chlamydia pneumoniae infection-… /Akt/mammalian target of
rapamycin (mTOR) signaling pathway … in neovascular atherosclerosis and in-stent restenosis 94 . …

… Chlamydia pneumoniae is known to induce atherosclerotic inflammation, pro-… was partially
reversed by the autophagy inhibitor 3-MA. The double-edged sword nature of autophagy may …

… , which will inform the development of increasingly … varicella-zoster virus, Chlamydia
pneumoniae, Mycoplasma spp. … ), and mammalian target of rapamycin (mTOR) signalling …

… TLR2 participates in Chlamydia pneumoniae infection–… The in‐stent restenotic arteries were
obtained from diseased … these pathological conditions, at least partially, by regulating VSMC …